P. Chollet

A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane.

J. Wanders, C. Twelves, P. Chollet, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer.

P. Soulié, E. Brain, J. Misset, 1997, European journal of cancer.

Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience.

M. Namer, J. Bonneterre, L. Mauriac, 1999, European journal of cancer.

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

C. Tournigand, M. Espié, B. Weber, 2019, The Lancet.

Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer.

P. Fumoleau, P. Fargeot, P. Kerbrat, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.